S&E BIO

About S&E BIO

S&E BIO, a clinical-stage biotechnology company established in 2019, is strategically positioned at the forefront of developing therapies for intractable neurological disorders. The company was founded by Professor Bang O Yeong, a distinguished neurologist with a profound background in stroke and stem cell research. His journey as a staff neurologist at Samsung Medical Center's Stroke and Cerebrovascular Center and a professor at Sungkyunkwan University School of Medicine directly informs the company's mission to address unmet medical needs in neurology. This deep clinical and academic expertise is the cornerstone of S&E BIO's approach to creating safe and effective treatments.

The company's core business revolves around the development of cell therapies derived from mesenchymal stem cell-derived extracellular vesicles, commonly known as exosomes. S&E BIO has developed a proprietary 3D culture system to optimize the production of these exosomes, which are engineered to carry therapeutic microRNAs. This technology is designed to promote neuroregeneration, offering a potential breakthrough for conditions where treatment options are scarce. The business model is focused on the research, clinical development, and eventual commercialization of these novel biopharmaceutical products.

S&E BIO's lead asset is SNE-101, an investigational therapy for acute ischemic stroke. This product has achieved a significant milestone as the first exosome-based therapy to receive approval for a Phase 1b clinical trial from Korea's Ministry of Food and Drug Safety. The therapy has demonstrated potential neuroregenerative, neuroprotective, and anti-inflammatory effects in pre-clinical studies, including in non-human primate models which are more reflective of human stroke pathology. S&E BIO is initially targeting patients suffering from acute stroke, moyamoya disease, chronic stroke, and dementia, with the broader goal of expanding its therapeutic pipeline to address a range of incurable diseases.

Financially, the Seoul-based company is privately held and venture capital-backed. It has successfully raised capital through several funding rounds, including a Series A, to advance its clinical programs. Key investors include Korea Investment Partners, Company K Partners, and KB Investment, reflecting confidence in the company's scientific platform and market potential.